Research
Energy balance
The primary efficacy endpoint is percentage change in body weight.
The trial will measure how effective efsubaglutide alfa is at reducing body weight.
StrongSupportsmedium confidence
The primary efficacy endpoint is percentage change in body weight.
Why this rating
Based on the structured design of the trial.
Source
Efsubaglutide alfa in adults with overweight or obesity: Protocol for a seamless, adaptive phase 2b/3 randomized, double‐blind, placebo‐controlled trial ( <scp>LIGHT</scp> 2)
WEIPING JIA et al. · Diabetes Obesity and Metabolism · 2026
DOI 10.1111/dom.70556
rct
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- LIGHT 2 is a seamless, adaptive phase 2b/3 trial evaluating the efficacy and safety of efsubaglutide alfa for chronic weight management in adults with overweight or obesity.Strong
- Key secondary endpoints include categorical weight-loss thresholds, changes in anthropometric and cardiometabolic measures, and comprehensive safety and tolerability assessments.Strong
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →